Dana Sager Selected Research

nepafenac (Nevanac)

1/2017	Efficacy of nepafenac ophthalmic suspension 0.1% in improving clinical outcomes following cataract surgery in patients with diabetes: an analysis of two randomized studies.
1/2017	Prospective randomised clinical trial to evaluate the safety and efficacy of nepafenac 0.1% treatment for the prevention of macular oedema associated with cataract surgery in patients with diabetic retinopathy.
2/2014	Once-daily nepafenac ophthalmic suspension 0.3% to prevent and treat ocular inflammation and pain after cataract surgery: phase 3 study.
1/2012	Evaluation of nepafenac in prevention of macular edema following cataract surgery in patients with diabetic retinopathy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Dana Sager Research Topics

Disease

4	Cataract (Cataracts) 01/2017 - 01/2012
3	Diabetic Retinopathy (Retinopathy, Diabetic) 01/2017 - 01/2012
1	Inflammation (Inflammations) 02/2014
1	Pain (Aches) 02/2014
1	Macular Edema 01/2012

Drug/Important Bio-Agent (IBA)

4	SuspensionsIBA 01/2017 - 01/2012
4	nepafenac (Nevanac)FDA Link 01/2017 - 01/2012
1	Pain-FreeIBA 02/2014

Therapy/Procedure

1	Intraocular Lens Implantation 01/2017